The scientists from Yale University developed a drinkable cocktail of designer molecules that shows promise in Alzheimer’s disease treatment. The new compound addresses a crucial first stage of the neurodegenerative disorder, and it can even restore the memory. However, these preliminary results have been obtained after studies on mice.
The binding of amyloid beta peptides to prion proteins generates a series of events that are devastating for the progression of the Alzheimer’s disease, such as the buildup of plaques, damaging immune system response, and destruction of the synapses.
“We wanted to find molecules that might have a therapeutic effect on this network,” explained Stephen Strittmatter, a professor of neuroscience and the director of the Alzheimer’s Disease Research Center at Yale University.
Stephen Strittmatter and his co-worker, Erik Gunther, analyzed tens of thousands of compounds seeking for those molecules that can interfere with the destructive prion protein interaction with amyloid beta peptides.
Drinkable Cocktail Of Designer Molecules Shows Promise In Alzheimer’s Disease Treatment
Luckily, the scientist found out that an old antibiotic showed promising effects in tackling the interaction of prion proteins with amyloid beta peptides. But the medicine became active only after decomposing it to form a polymer which retained the drug’s beneficial effects and was able to pass through the blood-brain barrier.
Then the researchers dissolved the polymeric substance and administered it to mice with an induced medical condition that mimicked Alzheimer’s disease. According to them, the mice recovered their lost memories while their brain synapses repaired.
Also, as reported by a team at Dartmouth University, with which the Yale University’s scientists collaborated, the same beneficial effects were recorded in mice with Creutzfeldt-Jakob Disease.
The drinkable cocktail of designer molecules shows promise in Alzheimer’s disease treatment, but the scientists must now test the compound for toxicity, that before commencing with the clinical trials for Alzheimer’s disease.